Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B
Juan Li, Auke P Verhaar, Qiuwei Pan, Robert Jacobus de Knegt, Maikel P Peppelenbosch Erasmus MC Cancer Institute, Erasmus MC - University Medical Center Rotterdam, Rotterdam, the Netherlands Background and aim: Caspase-cleaved cytokeratin 18 (CK18-Asp396) is a pot...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-08-01
|
| Series: | Clinical and Experimental Gastroenterology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/serum-levels-of-caspase-cleaved-cytokeratin-18-ck18-asp396-predict-sev-peer-reviewed-article-CEG |
| _version_ | 1830305856223182848 |
|---|---|
| author | Li J Verhaar AP Pan Q de Knegt RJ Peppelenbosch MP |
| author_facet | Li J Verhaar AP Pan Q de Knegt RJ Peppelenbosch MP |
| author_sort | Li J |
| collection | DOAJ |
| description | Juan Li, Auke P Verhaar, Qiuwei Pan, Robert Jacobus de Knegt, Maikel P Peppelenbosch Erasmus MC Cancer Institute, Erasmus MC - University Medical Center Rotterdam, Rotterdam, the Netherlands Background and aim: Caspase-cleaved cytokeratin 18 (CK18-Asp396) is a potential clinically useful biomarker in liver disease as it is released from hepatocytes during apoptosis. In this study, we investigated serum CK18-Asp396 levels in chronic hepatitis B (CHB). Patients and methods: Overall, 163 patients with CHB were included. Serum CK18‑Asp396 levels were determined by enzyme-linked immunosorbent assay (ELISA), and results were related to steatosis grade, histological activity index, inflammation score, and METAVIR fibrosis grade as well as to viral load, serum levels of liver enzymes, and albumin. Receiver operating characteristic analysis was used to evaluate the diagnostic performance of serum CK18-Asp396 levels for assessing disease activity. Results: A higher level of serum CK 18 concentrations was found in patients with significant inflammation vs no significant inflammation (378.5 [interquartile range {IQR}: 173.2–629.6] vs 137.3 [87.5–197.7], P < 0.05; approximately threefold increase) and in patients with significant fibrosis vs no significant fibrosis (177.8 [IQR: 120.8–519.1] vs 142.7 [IQR: 88.8–214.4], P < 0.05; 1.25-fold increase). There was no differential CK 18 level by degree of steatosis. CK 18 was an independent predictor of significant inflammation with an 82% specificity and a 94% negative predictive value. We found the strongest correlation of CK 18 with alanine aminotransferase and aspartate aminotransferase (both r = 0.52; P < 0.001), but less with albumin (r = -0.24; P < 0.05) and viral load (log) (r = 0.19; P < 0.05). Conclusion: CHB appears to be accompanied by continuous high levels of hepatocyte apoptosis as judged from serum CK 18, suggesting that elimination of the infected compartment constitutes a defensive strategy against disease. Accordingly, CK 18 works as an independent predictor of significant inflammation with a high specificity. Keywords: CHB, CK 18, apoptosis, steatosis, inflammation |
| first_indexed | 2024-12-19T10:01:56Z |
| format | Article |
| id | doaj.art-3e7f0136947c4b10871ac8e2d965dc8a |
| institution | Directory Open Access Journal |
| issn | 1178-7023 |
| language | English |
| last_indexed | 2024-12-19T10:01:56Z |
| publishDate | 2017-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical and Experimental Gastroenterology |
| spelling | doaj.art-3e7f0136947c4b10871ac8e2d965dc8a2022-12-21T20:26:37ZengDove Medical PressClinical and Experimental Gastroenterology1178-70232017-08-01Volume 1020320934214Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis BLi JVerhaar APPan Qde Knegt RJPeppelenbosch MPJuan Li, Auke P Verhaar, Qiuwei Pan, Robert Jacobus de Knegt, Maikel P Peppelenbosch Erasmus MC Cancer Institute, Erasmus MC - University Medical Center Rotterdam, Rotterdam, the Netherlands Background and aim: Caspase-cleaved cytokeratin 18 (CK18-Asp396) is a potential clinically useful biomarker in liver disease as it is released from hepatocytes during apoptosis. In this study, we investigated serum CK18-Asp396 levels in chronic hepatitis B (CHB). Patients and methods: Overall, 163 patients with CHB were included. Serum CK18‑Asp396 levels were determined by enzyme-linked immunosorbent assay (ELISA), and results were related to steatosis grade, histological activity index, inflammation score, and METAVIR fibrosis grade as well as to viral load, serum levels of liver enzymes, and albumin. Receiver operating characteristic analysis was used to evaluate the diagnostic performance of serum CK18-Asp396 levels for assessing disease activity. Results: A higher level of serum CK 18 concentrations was found in patients with significant inflammation vs no significant inflammation (378.5 [interquartile range {IQR}: 173.2–629.6] vs 137.3 [87.5–197.7], P < 0.05; approximately threefold increase) and in patients with significant fibrosis vs no significant fibrosis (177.8 [IQR: 120.8–519.1] vs 142.7 [IQR: 88.8–214.4], P < 0.05; 1.25-fold increase). There was no differential CK 18 level by degree of steatosis. CK 18 was an independent predictor of significant inflammation with an 82% specificity and a 94% negative predictive value. We found the strongest correlation of CK 18 with alanine aminotransferase and aspartate aminotransferase (both r = 0.52; P < 0.001), but less with albumin (r = -0.24; P < 0.05) and viral load (log) (r = 0.19; P < 0.05). Conclusion: CHB appears to be accompanied by continuous high levels of hepatocyte apoptosis as judged from serum CK 18, suggesting that elimination of the infected compartment constitutes a defensive strategy against disease. Accordingly, CK 18 works as an independent predictor of significant inflammation with a high specificity. Keywords: CHB, CK 18, apoptosis, steatosis, inflammationhttps://www.dovepress.com/serum-levels-of-caspase-cleaved-cytokeratin-18-ck18-asp396-predict-sev-peer-reviewed-article-CEGCHBCK-18apoptosissteatosisinflammation |
| spellingShingle | Li J Verhaar AP Pan Q de Knegt RJ Peppelenbosch MP Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B Clinical and Experimental Gastroenterology CHB CK-18 apoptosis steatosis inflammation |
| title | Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B |
| title_full | Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B |
| title_fullStr | Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B |
| title_full_unstemmed | Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B |
| title_short | Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B |
| title_sort | serum levels of caspase cleaved cytokeratin 18 ck18 asp396 predict severity of liver disease in chronic hepatitis b |
| topic | CHB CK-18 apoptosis steatosis inflammation |
| url | https://www.dovepress.com/serum-levels-of-caspase-cleaved-cytokeratin-18-ck18-asp396-predict-sev-peer-reviewed-article-CEG |
| work_keys_str_mv | AT lij serumlevelsofcaspasecleavedcytokeratin18ck18asp396predictseverityofliverdiseaseinchronichepatitisb AT verhaarap serumlevelsofcaspasecleavedcytokeratin18ck18asp396predictseverityofliverdiseaseinchronichepatitisb AT panq serumlevelsofcaspasecleavedcytokeratin18ck18asp396predictseverityofliverdiseaseinchronichepatitisb AT deknegtrj serumlevelsofcaspasecleavedcytokeratin18ck18asp396predictseverityofliverdiseaseinchronichepatitisb AT peppelenboschmp serumlevelsofcaspasecleavedcytokeratin18ck18asp396predictseverityofliverdiseaseinchronichepatitisb |